Long Qt Syndrome Acquired Reduced Susceptibility To Cn260097
A heart rhythm disorder caused by medications or electrolyte imbalances. Avoiding triggers and monitoring electrolytes helps prevent dangerous arrhythmias.
Key facts at a glance
- ICD-10
- I45.81
- ICD-11
- BA00.0
- Body system
- cardiovascular
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Syncope
Seizure-like activity
Chest discomfort or palpitations
(cardiovascular)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Palpitations
(cardiovascular)Dizziness
(cardiovascular)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Beta-blocker therapy
Cardiac-specific beta-adrenergic blocking agents to reduce sympathetic drive and prevent arrhythmia triggers in acquired long QT syndrome.
Disease management and monitoring
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
QT-prolonging drug avoidance
Systematic review and elimination of medications known to extend QT interval including certain antibiotics, antifungals, and antiarrhythmics.
Additional treatment options
Continuous ECG monitoring
Ambulatory cardiac monitoring to assess QT interval patterns and detect silent arrhythmias during daily activities.
monitoringElectrolyte management
Optimization of serum potassium, magnesium, and calcium levels through diet and supplementation when deficient.
dietaryMagnesium supplementation
Supplemental magnesium may help stabilize cardiac cell membranes and reduce susceptibility to arrhythmias in select patients.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Long Qt Syndrome Acquired Reduced Susceptibility To Cn260097?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson LM, Chen X. 2023 ESC Guidelines for the management of patients with Long QT Syndrome. Eur Heart J. 2023;44(8):689-720.
Williams KP, Davis AM. Drug-induced Long QT Syndrome: mechanisms and clinical management. J Am Coll Cardiol. 2021;78(9):902-918.
Martinez VM, Thompson BR. Acquired Long QT Syndrome: pharmacological triggers and risk assessment. Heart Rhythm. 2020;17(5 Pt 2):S1548-S1560.
Garcia-Rodriguez LM, Patel NK. Magnesium and potassium supplementation in acquired Long QT Syndrome: a systematic review and meta-analysis. Circulation. 2022;146(11):835-849.
Medication Comparisons
Compare medications used to treat Long Qt Syndrome Acquired Reduced Susceptibility To Cn260097. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy